A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs
A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs Moneycontrol Latest News Read More
